Synthetic Blood International Explores South Korean Partnership

Synthetic Blood International Inc. (SYBD; Kettering, OH) is discussing a potential partnership with a South Korean pharmaceutical company. The partnership, if established, would initially cover the development and registration of SYBD's Oxycyte, a perfluorocarbon based blood substitute, in South Korea. According to SYBD, the South Korean company is a leading manufacturer of pharmaceuticals, including large-volume intravenous products.

Robert Tao, SYBD's Far East agent for business development, initiated early discussions with the South Korean company, and has asked Robert Nicora, SYBD's president, to meet with the company. Nicora is expected to travel to South Korea soon to join further discussions. Nicora's visit may lead to the signing of a letter-of-intent between the two companies, at which time the South Korean company will be announced.

For more information: Robert Nicora, President and CEO, Synthetic Blood International Inc., 2685 Culver Avenue, Kettering, Ohio 45429. Tel: 937-298-6070. Fax: 937-298-6770.